Jefferies analyst Keith Devas lowered the firm’s price target on Kenvue (KVUE) to $23 from $25 and keeps a Buy rating on the shares. Macro headwinds continue to be felt more acutely in consumer health than other pockets of staples, says the analyst, who lowered targets and estimates across the firm’s consumer health coverage into Q3 earnings reports from the group.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KVUE:
- Kenvue price target lowered to $18 from $20 at Deutsche Bank
- Moderately bullish activity in Kenvue Inc with shares up 0.1%
- Starboard’s Smith says Kenvue exploring all alternatives
- Kenvue, Inc. (KVUE) Q3 Earnings Cheat Sheet
- Starboard Value Takes Aim at Tripadvisor: What Activist Pressure Could Mean for TRIP Stock